Clinical Trials

29 enrolled 12 charts

PSA Level Greater Than Two

NCT04484818 2026-05-05

Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

27 enrolled

Prostatic Neoplasms

NCT04513717 2026-05-04

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

2,753 enrolled

Prostatic Neoplasms

NCT05050084 2026-05-04

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

2,050 enrolled

Prostate Adenocarcinoma

NCT02115282 2026-04-30

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

608 enrolled 18 charts

Phase NA Active not recruiting

Breast Neoplasms

NCT02346253 2026-04-13

High-Dose Brachytherapy in Treating Patients With Prostate Cancer

146 enrolled

Prostatic Neoplasms

NCT03361735 2026-04-09

Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

25 enrolled 10 charts

Phase 4 Active not recruiting

Prostate Adenocarcinoma

NCT05161195 2026-04-02

Roll-over Study to Allow Continued Access to Ribociclib

134 enrolled

Breast Neoplasms

NCT04293393 2026-03-12

CARABELA

200 enrolled 27 charts

Phase 1 Active not recruiting

Breast Neoplasms

NCT05617885 2026-02-27

Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer

9 enrolled

Prostatic Neoplasms

NCT01786265 2026-02-20

Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer

310 enrolled

Prostatic Neoplasms

NCT02624973 2026-02-12

PETREMAC

200 enrolled

Breast Neoplasms

NCT01674140 2026-02-10

e3

1,939 enrolled 15 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT04455750 2026-02-05

CASPAR

61 enrolled

Prostatic Neoplasms

NCT03809000 2025-12-30

STEEL

188 enrolled 25 charts

Prostatic Neoplasms

NCT01723774 2025-12-09

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

84 enrolled 17 charts

Phase 1 Active not recruiting

Breast Neoplasms

NCT02023463 2025-11-25

Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer

25 enrolled

Prostatic Neoplasms

NCT04181203 2025-07-30

CARLHA-2

490 enrolled

Prostatic Neoplasms

NCT00567580 2025-05-09

Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

1,792 enrolled 27 charts

Prostatic Neoplasms

NCT03944434 2025-02-26

FACILE

116 enrolled

Breast Neoplasms

NCT00223145 2025-01-27

PCS III

600 enrolled

Prostatic Neoplasms

NCT02430103 2024-12-12

Study of Preservation of Ovarian Reserve During Chemotherapy for Young Breast Cancer Patients

Active not recruiting

349 enrolled

Phase 2/3 Active not recruiting

Breast Neoplasms

NCT02685397 2024-12-04

PCS IX

102 enrolled

Castration-resistant Prostate Cancer Patients with Oligometastases

NCT02344472 2024-06-04

Detect V / CHEVENDO (Chemo vs. Endo)

271 enrolled

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT05003752 2023-03-07

Hypo-Combi

40 enrolled

Prostatic Neoplasms, Radiation Injuries

NCT00430183 2023-02-09

Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

788 enrolled 10 charts

Prostatic Neoplasms

NCT02603679 2021-08-03

PREDIX LumB

181 enrolled

Breast Neoplasms

NCT02592083 2020-07-07

PREDIX LumA

10 enrolled